Phospho-KRT18 (Ser33) Antibody

What is the biological significance of KRT18 phosphorylation at Ser33?

Phosphorylation of Keratin 18 at Serine 33 plays a critical role in filament reorganization within cells. When KRT18 becomes phosphorylated at this residue, it undergoes structural modifications that affect intermediate filament dynamics. This post-translational modification is particularly important during cellular stress responses and mitosis.

Research indicates that phosphorylated KRT18 (Ser33) is involved in several key cellular processes:

• Reorganization of keratin filament networks

• Uptake of thrombin-antithrombin complexes by hepatic cells

• Participation in interleukin-6 (IL-6)-mediated barrier protection (in conjunction with KRT8)

• Delivery of mutated CFTR to the plasma membrane

The phosphorylation state of KRT18 at Ser33 serves as an important regulatory mechanism for cytoskeletal dynamics in epithelial cells, making it a valuable target for research in both normal and pathological conditions.

What applications are most suitable for Phospho-KRT18 (Ser33) antibodies?

Phospho-KRT18 (Ser33) antibodies can be utilized across multiple experimental platforms with varying efficacy. Based on validated applications from multiple sources, these antibodies are particularly suitable for:

• Western Blotting (WB): The recommended dilution ranges from 1:500-1:2000 depending on the specific antibody and sample type . WB allows for the quantitative assessment of phosphorylated KRT18 levels in cell or tissue lysates.

• Immunohistochemistry (IHC): Most antibodies perform well at dilutions of 1:50-1:300 . This application is particularly valuable for examining the spatial distribution of phosphorylated KRT18 in tissue sections.

• Immunofluorescence (IF): Effective dilutions typically range from 1:100-1:1000 . IF provides high-resolution imaging of phosphorylated KRT18 localization within cellular compartments.

• ELISA: Generally used at higher dilutions (1:5000-1:40000) for quantitative detection of phosphorylated KRT18 in solution.

• Immunoprecipitation (IP): Some Phospho-KRT18 (Ser33) antibodies have been validated for IP applications, allowing for the isolation and enrichment of phosphorylated KRT18 from complex protein mixtures .

When selecting the appropriate application, researchers should consider the cellular localization of phosphorylated KRT18, which is primarily cytoplasmic , and the specific biological question being addressed.

How should Phospho-KRT18 (Ser33) antibodies be stored and handled to maintain efficacy?

Proper storage and handling of Phospho-KRT18 (Ser33) antibodies are crucial for maintaining their specificity and sensitivity. Based on manufacturer recommendations:

• Storage temperature: Store antibodies at -20°C for long-term preservation . Some antibodies may be stored at -80°C for extended stability.

• Aliquoting: Upon receipt, divide the antibody solution into small aliquots to minimize freeze-thaw cycles, which can degrade antibody quality .

• Freeze-thaw cycles: Avoid repeated freeze-thaw cycles as this can lead to protein denaturation and reduced antibody efficacy .

• Working solution: For short-term use (1-2 weeks), antibodies can be stored at 4°C after dilution in appropriate buffer systems .

• Buffer composition: Most Phospho-KRT18 (Ser33) antibodies are supplied in PBS containing 50% glycerol, 0.5% BSA, and 0.02% sodium azide , which helps maintain stability during storage.

• Shipping conditions: While antibodies are typically shipped at 4°C , they should be transferred to -20°C storage immediately upon receipt for maximum longevity.

Proper adherence to these storage guidelines will ensure optimal antibody performance and reproducibility across experiments.

How does KRT18 phosphorylation at Ser33 affect its role in cancer progression?

The phosphorylation of KRT18 at Ser33 has significant implications for cancer biology, affecting multiple pathways related to tumor development and progression:

• Alternative Splicing Regulation: Research has demonstrated that KRT18 modulates alternative splicing of genes involved in cancer-related pathways . KRT18 knockdown experiments revealed alterations in splicing patterns of genes associated with:

  • Cell cycle regulation

  • Apoptosis

  • DNA repair

  • TGF-β receptor signaling

  • Negative regulation of type I interferon production

• Cell Proliferation and Apoptosis: Phosphorylated KRT18 influences cell survival mechanisms. Studies show that KRT18 knockdown:

  • Increased apoptotic levels in gastric cancer AGS cells

  • Inhibited proliferation in AGS cells

  • Affected expression of apoptosis-related genes including BIRC3, SERPINB2, RFK, TNFRSF9, and TNFAIP3

• Gene Expression Regulation: KRT18 impacts the expression of cancer-related genes, with 440 differentially expressed genes identified following KRT18 knockdown, including 153 up-regulated and 272 down-regulated genes .

• Splicing Factor Modulation: Phosphorylated KRT18 affects the alternative splicing of key splicing factors, including:

  • PTBP1 (verified casette exon)

  • HNRNPK (verified alternative 3' splice site)

  • HNRNPR and RBM39

These findings suggest that phosphorylated KRT18 functions as a regulatory hub that influences cancer progression through multiple mechanisms, including direct effects on cytoskeletal dynamics and indirect effects on gene expression and RNA processing.

What are the technical challenges in detecting phosphorylated KRT18 in different tissue types?

Detecting phosphorylated KRT18 (Ser33) across various tissue types presents several technical challenges that researchers must address:

• Tissue-specific expression levels: KRT18 expression varies significantly across tissues. It is primarily expressed in:

  • Single-layer epithelial tissues

  • Gastrointestinal tract epithelia

  • Respiratory tract tissues

  • Urogenital tract tissues

  • Endocrine and exocrine tissues

  • Mesothelial cells

• Phosphorylation dynamics: The phosphorylation state of KRT18 is highly dynamic and can be rapidly altered by:

  • Stress conditions

  • Cell cycle progression

  • Hypoxia (as shown in human proximal tubular epithelial cells treated with DMOG)

  • Phosphatase activity

• Fixation artifacts: Different fixation methods can affect phospho-epitope preservation:

  • Formalin fixation may mask phospho-epitopes

  • Alcohol-based fixatives may better preserve phosphorylation sites

  • Antigen retrieval methods must be optimized for phospho-specific detection

• Background issues in immunohistochemistry:

  • Non-specific binding can be problematic in tissues with high endogenous biotin

  • Cross-reactivity with other phosphorylated keratins must be considered

  • Optimization of blocking conditions is critical (using 0.5% BSA as in many antibody formulations)

• Validation across tissue types: Antibodies may perform differently across tissues:

  • Antibodies validated in breast carcinoma may require different conditions for other tissues

  • Positive controls appropriate for each tissue type should be included

• Preservation of phosphorylation status:

  • Rapid tissue processing is essential to preserve phosphorylation state

  • Phosphatase inhibitors should be included in all extraction buffers

  • Tissues should be snap-frozen or immediately fixed to prevent phosphatase activity

Addressing these challenges requires careful optimization of protocols for each specific tissue type and experimental question.

What methodological approaches can effectively validate the specificity of Phospho-KRT18 (Ser33) antibodies?

Validating the specificity of Phospho-KRT18 (Ser33) antibodies is crucial for ensuring reliable experimental results. Multiple complementary approaches should be employed:

• Peptide competition assays:

  • Incubate antibody with immunizing phosphopeptide prior to application

  • Compare staining patterns with and without peptide competition

  • Specific binding should be blocked by the phosphopeptide

  • Example: ab75747 at 1/50 dilution showed specific staining in human breast carcinoma tissue that was blocked by the immunizing peptide

• Phosphatase treatment controls:

  • Treat one sample set with lambda phosphatase

  • Compare phosphatase-treated and untreated samples

  • Signal should be lost or significantly reduced in phosphatase-treated samples

• Knockdown/knockout validation:

  • Use KRT18 knockdown or knockout models as negative controls

  • RNA-seq data can confirm knockdown efficiency (as shown in the KRT18-KD experiment where FPKM values significantly decreased)

• Phosphorylation induction:

  • Treat cells with phosphatase inhibitors (Calyculin A/Okadaic Acid)

  • This should increase detectable phosphorylated KRT18

  • Compare treated vs untreated samples to confirm signal enhancement

• Multiple antibody validation:

  • Use different antibodies targeting the same phospho-epitope

  • Compare staining patterns from different antibody clones

  • Consistent results across antibodies suggest true specificity

• Mass spectrometry confirmation:

  • Use immunoprecipitation followed by mass spectrometry

  • Confirm the presence of phosphorylated Ser33 in the immunoprecipitated protein

• Non-phospho specific antibody comparison:

  • Compare results with antibodies that detect total KRT18 regardless of phosphorylation state

  • This helps determine the proportion of KRT18 that is phosphorylated at Ser33

These validation approaches should be used in combination to provide comprehensive evidence for antibody specificity, ensuring reliable and reproducible results in phospho-KRT18 research.

How can researchers leverage Phospho-KRT18 (Ser33) antibodies to investigate cytoskeletal dynamics during cellular stress?

Investigating cytoskeletal dynamics during cellular stress using Phospho-KRT18 (Ser33) antibodies requires integrating multiple experimental approaches:

• Time-course experiments with cellular stressors:

  • Treatment with hypoxia-mimetic agents like DMOG (as shown in hPTECs )

  • Exposure to actual hypoxic conditions (1% oxygen)

  • Monitoring phosphorylation changes over time (24h, 72h intervals)

  • Quantification of phospho-KRT18/total KRT18 ratios at different timepoints

• Co-visualization of phospho-KRT18 with other cytoskeletal elements:

  • Dual immunofluorescence with phospho-KRT18 and F-actin (using phalloidin)

  • Analysis of spatial relationships between different cytoskeletal networks

  • Examination of filament reorganization in response to stress

• Live-cell imaging combined with fixed-cell analysis:

  • Transfect cells with fluorescently tagged KRT18

  • Monitor dynamics in live cells during stress

  • Fix cells at specific timepoints

  • Perform immunofluorescence with phospho-specific antibodies

  • Correlate live dynamics with phosphorylation status

• Cell spreading and migration assays:

  • Treat cells with stressors (e.g., DMOG) for 24h

  • Seed cells at low density (15,000 cells/cm²) on appropriate substrates

  • Measure cell spreading area using phalloidin staining

  • Correlate spreading capacity with phospho-KRT18 levels

• 3D culture systems for polarized epithelia:

  • Culture cells in transwell inserts to achieve polarization (8 days)

  • Apply stressors to polarized cells

  • Analyze phospho-KRT18 distribution in polarized vs. non-polarized conditions

• Quantitative analysis methods:

  • Western blotting with densitometric quantification

  • High-content imaging with automated analysis of filament organization

  • Correlation of phospho-KRT18 levels with phenotypic changes

These methodological approaches enable researchers to comprehensively investigate how KRT18 phosphorylation at Ser33 contributes to cytoskeletal reorganization during cellular stress responses, providing insights into fundamental mechanisms of cell adaptation.

What experimental designs are most effective for studying the relationship between KRT18 phosphorylation and alternative splicing regulation?

Investigating the relationship between KRT18 phosphorylation and alternative splicing regulation requires sophisticated experimental designs that integrate multiple methodologies:

• RNA-seq analysis following KRT18 manipulation:

  • Perform KRT18 knockdown using siRNA (as demonstrated in the research with AGS cells)

  • Construct biological replicates (minimum of three) for statistical robustness

  • Use advanced splicing analysis pipelines like ABLas to identify:

    • Known/annotated alternative splicing events (ASEs)

    • Novel/unannotated ASEs

    • Regulated alternative splicing events (RASEs)

  • Apply stringent cutoffs (p < 0.05, change in AS ratio ≥ 0.2) to identify high-confidence events

• Validation of splicing changes:

  • Design primers specific to alternatively spliced isoforms

  • Perform RT-qPCR to verify key splicing events

  • Focus on cancer-related genes showing alternative splicing (e.g., MAPK9/JNK2, STRA13)

  • Include both cancer-related genes and splicing factors in validation

• Correlation analysis between phosphorylation state and splicing patterns:

  • Treat cells with phosphatase inhibitors to increase KRT18 phosphorylation

  • Compare splicing patterns between phosphorylation-enhanced and normal conditions

  • Identify splicing events sensitive to phosphorylation status

• Splicing factor interaction studies:

  • Investigate interactions between phosphorylated KRT18 and splicing factors

  • Focus on splicing factors identified through co-expression analysis (correlation coefficient ≥ 0.6)

  • Examine alternative splicing of splicing factors themselves (e.g., PTBP1, HNRNPK)

• Network analysis approaches:

  • Construct networks connecting KRT18-coexpressed splicing factors and affected alternative splicing events

  • Apply correlation thresholds (correlation > 0.7 and p < 0.01) to identify significant associations

  • Perform GO enrichment analysis on genes with altered splicing to identify biological processes affected

• Functional validation of altered splicing:

  • Express alternatively spliced isoforms in cellular models

  • Assess functional outcomes related to cancer hallmarks:

    • Apoptosis

    • Proliferation

    • Cell cycle regulation

    • Migration

These experimental designs provide a comprehensive framework for elucidating how KRT18 phosphorylation influences alternative splicing regulation, particularly in cancer contexts, revealing potential mechanisms by which cytoskeletal proteins can impact gene expression at the post-transcriptional level.

What are the critical considerations for optimizing Western blot protocols for Phospho-KRT18 (Ser33) detection?

Optimizing Western blot protocols for Phospho-KRT18 (Ser33) detection requires attention to several critical factors:

• Sample preparation:

  • Include phosphatase inhibitors in lysis buffers to preserve phosphorylation status

  • Process samples quickly and maintain cold temperatures throughout

  • Consider using phosphatase inhibitors like Calyculin A/Okadaic Acid to enhance phosphorylation signal

  • Use appropriate lysis buffers that efficiently extract cytoskeletal proteins

• Gel electrophoresis conditions:

  • Use gels with appropriate percentage (typically 10-12% SDS-PAGE) for the 47 kDa KRT18 protein

  • Consider gradient gels for better resolution of phosphorylated isoforms

  • Load adequate protein amounts (typically 20-50 μg per lane)

• Transfer conditions:

  • Optimize transfer time and voltage for proteins in the 45-50 kDa range

  • Consider using PVDF membranes which may offer better retention of phosphoproteins

  • Validate transfer efficiency with reversible protein stains

• Blocking optimization:

  • Use 5% BSA in TBS-T rather than milk (milk contains phosphoproteins that can interfere)

  • Optimize blocking time (typically 1 hour at room temperature or overnight at 4°C)

  • Consider commercial blocking buffers specifically designed for phosphoprotein detection

• Antibody dilution and incubation:

  • Use manufacturer-recommended dilutions (typically 1:500-1:2000)

  • Incubate primary antibody overnight at 4°C for optimal signal-to-noise ratio

  • Prepare antibody in 5% BSA/TBS-T solution

• Controls:

  • Include positive control lysates (e.g., A431 cell extracts as used with ab75747)

  • Run a phosphatase-treated sample as negative control

  • Consider including peptide competition controls

• Detection optimization:

  • Use enhanced chemiluminescence (ECL) or fluorescence-based detection systems

  • Optimize exposure times to avoid saturation

  • Consider using digital imaging systems for more quantitative analysis

• Quantification:

  • Normalize phospho-KRT18 signal to total KRT18 to account for expression differences

  • Use appropriate software (ImageJ, Image Lab, etc.) for densitometric analysis

  • Present data as fold-change in phosphorylation rather than absolute values

Following these optimized protocols will enhance the specificity, sensitivity, and reproducibility of Phospho-KRT18 (Ser33) detection in Western blot applications.

How can researchers effectively use Phospho-KRT18 (Ser33) antibodies in multiplex immunofluorescence applications?

Implementing multiplex immunofluorescence with Phospho-KRT18 (Ser33) antibodies requires careful planning and optimization:

• Antibody selection and validation:

  • Choose Phospho-KRT18 (Ser33) antibodies raised in compatible host species (rabbit polyclonals are most common)

  • Validate antibodies individually before multiplexing

  • Test for cross-reactivity with other targets in the multiplex panel

  • Confirm that secondary antibodies do not cross-react

• Multiplex panel design:

  • Pair Phospho-KRT18 (Ser33) with complementary markers:

    • Total KRT18 (from different host species) to determine phosphorylation ratio

    • Other cytoskeletal components (F-actin using phalloidin)

    • Cell-type specific markers for tissue context

    • Signaling pathway components relevant to KRT18 function

• Sequential staining approach:

  • Perform sequential rather than simultaneous staining if antibodies are from the same species

  • Use fluorophore-conjugated Fab fragments to block first primary antibody

  • Apply careful washing between steps

  • Consider tyramide signal amplification for weak signals

• Spectral considerations:

  • Select fluorophores with minimal spectral overlap

  • Include single-stain controls for spectral unmixing

  • Consider using quantum dots for narrow emission spectra

  • Use fluorophores that are photostable for extended imaging sessions

• Protocol optimization:

  • Optimize fixation to preserve phospho-epitopes (4% paraformaldehyde is often suitable)

  • Test various antigen retrieval methods for each antibody in the panel

  • Determine optimal antibody concentration for each target (typically 1:100-1:500 for IF)

  • Include longer washing steps to reduce background

• Image acquisition settings:

  • Use confocal microscopy for better resolution of cytoskeletal structures

  • Adjust laser power and detector gain for each channel separately

  • Acquire z-stacks for 3D analysis of filament networks

  • Use consistent settings across experimental groups

• Quantitative analysis approaches:

  • Develop automated image analysis workflows for colocalization analysis

  • Measure phospho-KRT18/total KRT18 ratios in different cellular compartments

  • Quantify filament organization parameters (length, thickness, orientation)

  • Correlate phospho-KRT18 levels with other markers in single cells

• Biological controls:

  • Include treatment conditions known to affect phosphorylation (e.g., DMOG, hypoxia)

  • Compare normal vs. pathological tissues (e.g., breast carcinoma)

  • Include phosphatase-treated controls

These methodological considerations will enable researchers to effectively implement multiplex immunofluorescence strategies with Phospho-KRT18 (Ser33) antibodies, providing spatial context for phosphorylation events within the cellular architecture.

What protocols are recommended for immunoprecipitating phosphorylated KRT18 for downstream applications?

Immunoprecipitation (IP) of phosphorylated KRT18 requires specialized protocols to maintain phosphorylation status and ensure specificity:

• Cell/tissue preparation:

  • Harvest cells at 70-80% confluence for optimal KRT18 expression

  • Add phosphatase inhibitors (sodium orthovanadate, sodium fluoride, β-glycerophosphate) to all buffers

  • Use mild lysis conditions to preserve protein-protein interactions

  • Recommended lysis buffer: 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, with protease and phosphatase inhibitors

• Pre-clearing step:

  • Pre-clear lysates with protein A/G beads for 1 hour at 4°C

  • Remove non-specific binding proteins by centrifugation

  • Transfer pre-cleared supernatant to new tube

• Antibody binding:

  • Add 2-5 μg of Phospho-KRT18 (Ser33) antibody per 1 mg of total protein

  • Validated antibodies for IP include monoclonal IB4 clone

  • Incubate overnight at 4°C with gentle rotation

  • Add fresh protein A/G beads and incubate for additional 2-4 hours

• Washing conditions:

  • Perform 4-5 washes with decreasing salt concentrations

  • Include phosphatase inhibitors in all wash buffers

  • Use gentle resuspension techniques to avoid losing beads

• Elution methods:

  • For Western blot: Elute directly in 2X SDS sample buffer at 95°C for 5 minutes

  • For mass spectrometry: Use non-denaturing elution with competing phosphopeptide

  • For functional assays: Consider native elution conditions with phosphopeptide competition

• Controls and validation:

  • Include IgG-matched control IPs

  • Perform parallel IPs with total KRT18 antibodies

  • Validate IP specificity by Western blot

  • Consider phosphatase treatment of a portion of the immunoprecipitate as negative control

• Downstream applications:

  • For MS analysis: Digest eluted proteins with trypsin and enrich for phosphopeptides

  • For interaction studies: Analyze co-immunoprecipitated proteins by Western blot or MS

  • For functional assays: Use immunoprecipitated phospho-KRT18 in in vitro filament assembly tests

• Quantification approaches:

  • Compare phospho-KRT18 levels between experimental conditions

  • Normalize to total KRT18 levels in input samples

  • Analyze changes in protein interactions under different conditions

These protocol recommendations will facilitate successful immunoprecipitation of phosphorylated KRT18 for various downstream applications, enabling researchers to investigate the functional consequences of KRT18 phosphorylation at Ser33.

How can Phospho-KRT18 (Ser33) be utilized as a biomarker in cancer research?

Phospho-KRT18 (Ser33) has significant potential as a cancer biomarker due to its roles in cytoskeletal dynamics and gene regulation:

• Expression profile in cancer tissues:

  • KRT18 shows significantly higher expression in stomach adenocarcinoma compared to normal tissues based on TCGA database analysis

  • Phosphorylated KRT18 can be detected in various cancer types including:

    • Breast carcinoma (validated by IHC staining with ab75747)

    • Gastric cancer cell lines (AGS cells)

    • Hepatocellular carcinoma (expresses only cytokeratins 8 and 18)

• Association with cancer-related pathways:

  • KRT18 modulates alternative splicing of genes involved in:

    • Cell cycle regulation

    • Apoptotic processes

    • DNA repair mechanisms

    • TGF-β receptor signaling

    • RIG-I-like receptor signaling

  • These pathways are frequently dysregulated in cancer development

• Methodological approaches for biomarker validation:

  • Tissue microarray analysis across multiple cancer types

  • Correlation of phospho-KRT18 levels with:

    • Clinical parameters (stage, grade)

    • Patient outcomes (survival, response to therapy)

    • Molecular subtypes of cancer

• Functional implications in cancer biology:

  • KRT18 knockdown increases apoptosis and inhibits proliferation in gastric cancer cells

  • Phosphorylation at Ser33 may serve as an indicator of altered cytoskeletal dynamics in cancer cells

  • Changes in KRT18 phosphorylation state could reflect cancer-specific metabolic adaptations

• Technical considerations for biomarker development:

  • Standardize detection methods (IHC protocols, scoring systems)

  • Establish thresholds for positivity in different cancer types

  • Validate antibody specificity across diverse tumor samples

  • Develop quantitative assays for phospho/total KRT18 ratios

• Integration with other biomarkers:

  • Combine phospho-KRT18 with other cytoskeletal markers

  • Incorporate into multi-marker panels for improved specificity

  • Correlate with established cancer biomarkers

• Potential clinical applications:

  • Early detection of carcinomas

  • Monitoring treatment response

  • Identification of aggressive phenotypes

  • Selection of patients for targeted therapies

By implementing these approaches, researchers can evaluate the utility of Phospho-KRT18 (Ser33) as a biomarker for cancer diagnosis, prognosis, and treatment selection, potentially improving clinical management of various cancer types.

What experimental approaches can elucidate the relationship between KRT18 phosphorylation and cytoskeletal reorganization in epithelial-mesenchymal transition?

Investigating the relationship between KRT18 phosphorylation and cytoskeletal reorganization during epithelial-mesenchymal transition (EMT) requires integrated experimental approaches:

• EMT induction models:

  • TGF-β treatment of epithelial cells

  • Hypoxia exposure (1% oxygen) as demonstrated in hPTECs

  • Expression of EMT-inducing transcription factors (SNAIL, TWIST, ZEB)

  • 3D organoid culture systems transitioning to invasive phenotypes

• Temporal analysis of phosphorylation dynamics:

  • Time-course experiments during EMT induction (24h, 48h, 72h timepoints)

  • Western blotting with phospho-specific and total KRT18 antibodies

  • Quantification of phospho/total ratios throughout EMT progression

  • Correlation with expression of EMT markers (E-cadherin, Vimentin)

• High-resolution imaging approaches:

  • Live-cell imaging with fluorescently tagged KRT18

  • Fixed-cell immunofluorescence with Phospho-KRT18 (Ser33) antibodies (1:100-1:500 dilution)

  • Super-resolution microscopy to capture filament reorganization

  • Multi-color imaging to co-visualize:

    • Phospho-KRT18 (Ser33)

    • F-actin (using phalloidin)

    • Adherens junction proteins

    • Focal adhesion components

• Functional assays linking phosphorylation to cell behavior:

  • Cell spreading assays on various substrates

  • Migration and invasion assays correlating with phosphorylation status

  • Assessment of mechanical properties (stiffness, deformability)

  • Attachment and detachment kinetics

• Molecular manipulation approaches:

  • Expression of phosphomimetic (S33D) and phosphodeficient (S33A) KRT18 mutants

  • Analysis of filament organization in mutant-expressing cells

  • Rescue experiments in KRT18 knockdown cells

  • CRISPR/Cas9 genome editing of endogenous KRT18

• Biochemical analysis of keratin solubility:

  • Fractionation of cells into detergent-soluble and insoluble components

  • Quantification of phospho-KRT18 distribution between fractions

  • Analysis of changes in solubility during EMT progression

• Interaction studies:

  • Co-immunoprecipitation of phospho-KRT18 binding partners during EMT

  • Proximity ligation assays to detect interactions in situ

  • Mass spectrometry to identify novel interaction partners

• Correlation with signaling pathways:

  • Inhibitor studies targeting kinases involved in KRT18 phosphorylation

  • Analysis of IL-6 signaling components (KRT18 works with KRT8 in IL-6-mediated barrier protection)

  • Investigation of cross-talk with TGF-β signaling (enriched in KRT18-affected alternative splicing)

These experimental approaches provide a comprehensive framework for elucidating how KRT18 phosphorylation at Ser33 contributes to cytoskeletal reorganization during EMT, potentially revealing new therapeutic targets for preventing cancer metastasis.

How does KRT18 phosphorylation influence its interaction with splicing factors and RNA processing machinery?

The relationship between KRT18 phosphorylation and RNA processing represents an emerging area of research with significant implications for gene regulation:

• Evidence for KRT18-splicing factor relationships:

  • Coexpression analysis identified 1,278 KRT18-coexpressed genes in gastric cancer samples

  • Significant overlap with RNA splicing-related genes (19 genes)

  • Regulated alternative splicing events (RASEs) in KRT18-high vs. KRT18-low samples enriched in RNA splicing functions

• Network analysis approaches:

  • Construction of networks between KRT18-coexpressed splicing factors and affected alternative splicing events

  • Identification of 463 SF-ASE pairs with high correlation (>0.7, p<0.01)

  • Network involving 10 splicing factors and 272 alternative splicing events

  • Enrichment analysis showing these networks affect apoptosis, RNA splicing, transcription, and mitosis

• Experimental validation methodologies:

  • RT-qPCR verification of alternative splicing in key splicing factors:

    • PTBP1 (casette exon)

    • HNRNPK (alternative 3' splice site)

    • HNRNPR and RBM39

  • Design of primers specific for alternatively spliced isoforms

  • Comparison between KRT18 knockdown and control conditions

• Phosphorylation-dependent interactions:

  • Immunoprecipitation of phospho-KRT18 followed by mass spectrometry

  • Comparison of interactomes between phosphorylated and non-phosphorylated KRT18

  • RNA-immunoprecipitation to identify directly bound RNA targets

  • Proximity ligation assays to detect interactions in situ

• Subcellular localization studies:

  • Immunofluorescence microscopy to determine colocalization between:

    • Phospho-KRT18 (Ser33) (using antibodies at 1:100-1:500 dilution)

    • Splicing factors (PTBP1, HNRNPK)

    • Nuclear speckles (SC35)

  • Analysis of phospho-KRT18 nuclear/cytoplasmic distribution

  • Live-cell imaging to track dynamics during transcriptional activation

• Functional consequences of interactions:

  • Minigene splicing assays with and without phospho-KRT18

  • Global analysis of alternative splicing patterns using RNA-seq

  • Correlation between phospho-KRT18 levels and specific splicing patterns

  • Identification of direct vs. indirect effects on RNA processing

• Signaling pathway integration:

  • Investigation of kinases that phosphorylate both KRT18 and splicing factors

  • Analysis of phosphorylation changes during cellular stress responses

  • Correlation with cell cycle-dependent phosphorylation events

• Disease relevance:

  • Comparison of phospho-KRT18/splicing factor interactions between:

    • Normal tissues

    • Cancer tissues

    • Different cancer subtypes

  • Correlation with patient outcomes and treatment responses

These methodological approaches provide a framework for investigating how KRT18 phosphorylation influences RNA processing machinery, potentially revealing new mechanisms by which cytoskeletal proteins can regulate gene expression at the post-transcriptional level.